Core Viewpoint - DBV Technologies has successfully raised €166.7 million through the full exercise of ABSA and BS Warrants, which will support the launch of the VIASKIN® Peanut patch for children aged 4 to 7 years in the U.S., pending approval [1][11]. Financing Details - The financing involved the issuance of 34,090,004 ABSA Warrants and 71,005,656 BS Warrants, leading to the issuance of 59,657,507 new ordinary shares and up to 124,259,898 pre-funded warrants [1][5]. - The exercise price for the ABSA Warrants was €1.5939, while the BS Warrants had an exercise price of €1.5764 [1][6]. Use of Proceeds - The gross proceeds from the exercise will be utilized for working capital, general corporate purposes, and to finance the preparation and submission of a potential Biologics License Application (BLA) for the VIASKIN® Peanut patch [10][11]. - The total financing, including potential exercises of outstanding warrants, is estimated to reach approximately €284.5 million [10]. Shareholder Impact - The issuance of new shares will dilute existing shareholders' equity, with ownership interest for a shareholder holding 1.00% of the Company's share capital decreasing to 0.78% on a non-diluted basis after the issuance [15]. - The shareholding structure will change post-issuance, with Baker Brothers Investments retaining 8.64% and Janus Henderson acquiring 7.54% of the diluted share capital [17]. Company Overview - DBV Technologies is a late-stage biopharmaceutical company focused on developing treatments for food allergies using its proprietary VIASKIN® patch technology [19]. - The company is headquartered in Châtillon, France, with operations in North America [20].

Group 1 - The document provides updated information regarding the total number of voting rights and shares of the company as of December 31, 2025, replacing previous information published on January 5, 2026 [1] - The total number of shares as of December 31, 2025, is 235,670,864, which is also the total number of voting rights [2] - The net total of voting rights, which excludes shares without voting rights, is 235,596,284 [2]

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345  Date  Total number of shares Total number of voting rights12/31/2025 232,207,589  Total gross of voting rights: 232,207,589  Total net* of voting rights: 232,133,009  * Net total = total number of voting rights attached to shares – shares without votin ...

Group 1: Palvella Therapeutics Inc. (PVLA) - Palvella is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases with no FDA-approved treatments [2] - Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and has a multi-billion-dollar market opportunity if approved [2] - The stock rose from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, before pulling back to $99.88 [3] Group 2: Cidara Therapeutics Inc. (CDTX) - Cidara is developing a preventive therapy for influenza and has agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion [4] - The stock was trading at $18.98 when profiled on November 21, 2024 [4] Group 3: Celcuity Inc. (CELC) - Celcuity is focused on targeted therapies for oncology, with its lead drug candidate Gedatolisib aimed at breast and prostate cancers [5] - The stock increased from $12.60 on December 4, 2024, to an all-time high of $112.64 on December 12, 2025, before retreating to $99.16 [6] Group 4: Nanobiotix (NBTX) - Nanobiotix is a late-stage clinical biotechnology company developing physics-based therapies for cancer [7] - Its lead candidate, NBTXR3, is undergoing a phase III study for head and neck squamous cell carcinoma, with interim data expected in the first half of 2027 [8] - The stock rose from $12.23 on September 19, 2025, to a high of $30.35 on October 13, 2025, before trading around $21 [10] Group 5: Terns Pharmaceuticals Inc. (TERN) - Terns Pharma is developing small-molecule candidates for serious diseases, with TERN-701 targeting chronic myeloid leukemia [12] - Recent data showed a 75% major molecular response rate among patients receiving higher doses [13] - The stock increased from $5.98 on August 6, 2025, to an all-time high of $48.26 on December 10, 2025, before pulling back to around $40 [14] Group 6: DBV Technologies S.A. (DBVT) - DBV Technologies is developing an epicutaneous immunotherapy for food allergies, with its lead product, the VIASKIN Peanut patch, showing positive results in a phase 3 study [15] - The company aims to submit a Biologics License Application in the first half of 2026, with potential sales of $1.5 billion by 2030 if approved [15] - The stock rose from $10.64 on October 2, 2025, to a high of $26.18 on December 17, 2025, before trading around $19 [16] Group 7: Nutex Health Inc. (NUTX) - Nutex Health reported a significant turnaround from a $424 million net loss in 2022 to a $59 million net income for the nine months ended September 30, 2025 [17] - Revenue increased from $219 million in 2022 to $723.6 million in the first nine months of 2025 [17] - The stock rose from $33.56 on November 25, 2024, to a 52-week high of $193.07 before closing at $182.23 [18] Group 8: Inhibrx Biosciences Inc. (INBX) - Inhibrx is developing biologic therapies for cancer, with Ozekibart showing significant improvement in progression-free survival in chondrosarcoma [19] - The company plans to submit a biologics license application for Ozekibart in the second quarter of 2026 [20] - The stock rose from $18.35 on July 8, 2025, to an all-time high of $94.57 on December 22, 2025, before trading around $77 [21] Group 9: GRAIL Inc. (GRAL) - GRAIL focuses on early cancer detection with its Galleri test, which is not yet FDA-approved [23] - The company expects to submit a PMA for the Galleri test in Q1 2026 [23] - The stock increased from $48.50 on September 26, 2025, to a high of $115.76 on November 25, 2025, before trading around $88 [24] Group 10: Cogent Biosciences Inc. (COGT) - Cogent is developing precision therapies for genetically defined diseases, with Bezuclastinib being its lead candidate [25] - The company submitted its first NDA to the FDA for Non-AdvSM, with additional submissions planned for GIST and advanced systemic mastocytosis [26] - The stock rose from $7.25 on July 2, 2025, to a 52-week high of $43.73 on December 8, 2025, before easing back to around $35 [26] Group 11: Sol-Gel Technologies Ltd. (SLGL) - Sol-Gel has two FDA-approved products for dermatological conditions and is developing investigational products [27] - A phase III trial for SGT-610 is ongoing, with results expected in Q4 2026 [28] - The stock rose from $7.26 on May 7, 2025, to a high of $52.26 on October 6, 2025, before trading around $43 [28] Group 12: Zenas BioPharma Inc. (ZBIO) - Zenas is focused on therapies for autoimmune diseases, with Obexelimab in phase 3 trials for IgG4-RD [29] - Positive data from a phase 2 trial in multiple sclerosis showed a 95% reduction in new lesions [30] - The stock rose from $8.79 on December 17, 2024, to a high of $44.60 on December 24, 2025, before pulling back to around $35 [31]

Group 1 - U.S. stock futures were mostly flat, with Nasdaq 100 futures slipping around 0.01% [1] - Sidus Space, Inc. announced a public offering of 19,230,800 shares at $1.30 per share, leading to a 39.2% decline in its shares to $1.39 in pre-market trading [1] Group 2 - Starfighters Space Inc shares dipped 23.2% to $24.19 after a significant gain of over 370% on Monday [2] - ECD Automotive Design, Inc. fell 15.4% to $0.1650 following a 1-for-5 reverse stock split announcement [2] - CapsoVision Inc dipped 5.6% to $12.35, while Rocket Lab Corp fell 5.3% to $73.46 after a previous 10% jump [2] - Intuitive Machines Inc declined 5.2% to $15.82 despite a price target increase from $14 to $20 by B. Riley Securities [2] - Firefly Aerospace Inc shares declined 4.4% to $27.33 after a 16% increase due to joining the Russell 2000 and Russell 3000 indexes [2] - AST SpaceMobile Inc shares declined 3.1% to $83.82 after a 14% surge related to new satellite details [2]

Group 1 - Clearwater Analytics Holdings, Inc. is being acquired by a consortium of private equity firms led by Permira and Warburg Pincus for approximately $8.4 billion, including debt [1] - Following the acquisition announcement, Clearwater Analytics shares increased by 7.6% to $23.93 in pre-market trading [1] Group 2 - Autozi Internet Technology (Global) Ltd. experienced a significant surge of 60% to $4.00 in pre-market trading after confirming a $90 million initial equity investment [4] - Datavault AI Inc. saw a rise of 34.8% to $1.31 in pre-market trading due to the announcement of two foundational U.S. patents related to blockchain-driven content licensing [4] - Vision Marine Technologies Inc. rose by 30.3% to $0.3270 after closing a public offering [4] - Sidus Space, Inc. increased by 20.7% to $1.40 after a previous jump of 35% [4] - Hycroft Mining Holding Corporation gained 14.2% to $18.77 after a 7% increase on the previous trading day [4] - Creative Media & Community Trust Corporation shares jumped 13.2% to $3.61 after a 7% gain on Friday [4] - ABIVAX Société Anonyme gained 10.2% to $126.64 in pre-market trading [4] Group 3 - Luminar Technologies, Inc. fell sharply by 54.8% to $0.2728 after announcing voluntary Chapter 11 proceedings [4] - Mint Incorporation Limited declined by 14.4% to $0.41 after a significant increase of over 75% on Friday [4] - Culp, Inc. reported mixed second-quarter financial results, leading to a 10.1% drop to $3.11 in pre-market trading [4] - Rising Dragon Acquisition Corp. declined by 9.5% to $9.42 following a trust amendment announcement [4] - Hyperscale Data, Inc. fell by 9.2% to $0.2335 after announcing an "at-the-market" offering of common stock [4]

Core Insights - DBV Technologies S.A. (NASDAQ:DBVT) is recognized as one of the 12 best multibagger stocks to consider for investment heading into 2026 due to strong one-year returns and upside potential [1] Group 1: Trial Results and Impact - The pivotal VITESSE study for DBV Technologies met its primary endpoint, showing that after 12 months of treatment with the VIASKIN Peanut patch, 46.6% of children achieved clinically meaningful desensitization compared to 14.8% on placebo, indicating a statistically significant outcome [3] - The trial also demonstrated a favorable safety profile, high compliance, and low discontinuation rates, reinforcing the patch's potential as a non-invasive treatment option for peanut allergies [3] Group 2: Analyst Ratings and Price Targets - H.C. Wainwright raised its price target on DBV Technologies from $35 to $40 while maintaining a "Buy" rating, citing the Phase 3 VITESSE trial as a significant milestone that reduces risks associated with the VIASKIN Peanut program [2] - Citizens also increased its price target from $21 to $45, maintaining an "Outperform" rating, and noted that the success of the VITESSE trial could unlock $181 million in cash, potentially supporting a U.S. launch for the product in the pediatric population [4] Group 3: Company Focus and Market Position - DBV Technologies specializes in developing non-invasive immunotherapies, particularly through its VIASKIN patch technology, which aims to desensitize patients with food allergies, addressing significant unmet needs in pediatric care [5] - The convergence of clinical success and financial flexibility positions DBV Technologies favorably as it approaches regulatory submission for its products [5]

Group 1: Toro Co Performance - Toro Co reported quarterly earnings of 91 cents per share, exceeding the analyst consensus estimate of 87 cents per share [1] - The company achieved quarterly sales of $1.066 billion, surpassing the analyst consensus estimate of $1.048 billion [1] - Following the earnings report, Toro's shares rose by 7% to $77.82 [1] Group 2: Other Notable Stock Movements - DBV Technologies SA shares increased by 35.5% to $24.36 after meeting primary endpoints in the Phase 3 VITESSE trial [3] - Udemy Inc gained 26.5% to $6.79 due to an all-stock merger agreement with Coursera [3] - Kodiak Sciences Inc jumped 16.7% to $28.16 after announcing a public offering of common stock [3] - Hut 8 Corp rose 16.3% to $42.88 following a partnership to accelerate AI infrastructure deployment and a $7.0 billion lease agreement [3] - Canopy Growth Corp increased by 16.2% to $2.13 amid reports of potential reclassification of marijuana [3] - Recursion Pharmaceuticals Inc gained 13.2% to $4.76 after an upgrade from JP Morgan [3] - Two Harbors Investment Corp surged 13.2% to $11.21 due to an acquisition announcement [3] - Quantumscape Corp gained 7.7% to $11.66 after signing a joint development agreement with a top-10 global automaker [3] - Jabil Inc reported better-than-expected earnings, leading to a 7% increase in shares to $227.50 [3]

DBV Technologies S.A. (NASDAQ:DBVT) on Tuesday released data from the VITESSE Phase 3 study assessing the safety and efficacy of VIASKIN Peanut patch for peanut-allergic children aged 4 to 7 years.DBV Technologies stock is challenging resistance. What’s driving DBVT to record levels?Trial DataThe pivotal trial met its primary endpoint.VIASKIN Peanut demonstrated a statistically significant treatment effect, with 46.6% of children in the VIASKIN Peanut arm meeting the treatment responder criteria after 12 mo ...

DBV Technologies盘前大涨超30%。消息上，DBV Technologies宣布了VIASKIN花生贴片在4-7岁花生过 敏儿童中的3期VITESSE试验取得了积极的初步结果，达到了其主要终点。针对4-7岁儿童的BLA提交按 计划将在2026年上半年进行。 | DBVT DBV Technologies | | | | --- | --- | --- | | 17 980 L -0.310 -1.69% | | 收盘价 12/16 16:00 美东 | | 23.400↑ 5.420 +30.14% | | 盘前价 12/17 04:11 美东 | | 三五249 月 ♥ 白选 | | ● 快捷交易 | | 最高价 18.280 | 开盘价 17.500 | 成交量 86.74万 | | 最低价 17.500 | 昨收价 18.290 | 成交额 2540.84万 | | 平均价 29.292 | 市盈率TM 亏损 | 总市值 7.22亿 (1) | | 振 幅 4.26% | 市盈率(静) 亏损 | 总股本 4013.36万 | | 换手率 3.85% | 市净率 13.652 | 流通值 4 ...